Year-over-year earnings per share growth for the last twelve months: Zymeworks Inc. (ZYME)

zymeworks.com (ZYME) - corporate logo

Zymeworks Inc. develops multispecific antibodies to combat severe tumors, addressing a broad immuno-oncology market. Revenues are based on platform licensing and partner milestone payments for research stages. The breakthrough potential of zanidatamab and an active pipeline define the current innovation cycle. The quarterly change in earnings per share demonstrates growth dynamics, where the metric value is 984.30, helping to identify fundamental liquidity trends.

Zymeworks Inc (ZYME) Year-over-year net earnings per share growth for the last 12 months: for the period 07/04/2022 - 11/12/2026

Comprehensive metric breakdowns and analytics for Zymeworks Biopharmaceuticals (ZYME)

- share price and expert price forecast:
Stock Price Zymeworks|ZYME - Analyst Median Target
- company stock exchange capitalization indicators:
Market Value Zymeworks Corp|ZYME - Real Price to Acquire Entire Company
- book capitalization data:
Net Assets per Single Share Zymeworks|ZYME - Company Net Assets|Market Cap to Net Assets Ratio zymeworks.com|ZYME - Company Total Assets
- debt and liquidity details:
Debt to Equity Zymeworks Inc.|ZYME - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Zymeworks Inc.|ZYME - Company Cumulative Debt|Debt to Book Value Zymeworks Corp|ZYME - Long-Term Indebtedness|Company Current Liabilities Zymeworks|Quick Ratio zymeworks.com
- earnings and market multiples details:
ZYME - Final Profit|Projected Future Earnings Zymeworks Inc.|ZYME - Market Cap to Earnings|Future Price to Earnings Zymeworks Corp|ZYME - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Zymeworks Corp|ZYME - Operating profit EBITDA|Earnings per share for the last twelve months Zymeworks|ZYME - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months zymeworks.com|ZYME - Earnings per share growth rate in current year|Expected earnings per share growth for next year Zymeworks Inc.
Comprehensive company analysis:Zymeworks, ZYME
Manufactured product of Zymeworks Inc.

Cancer immunotherapy from Zymeworks Inc. (ZYME) possesses absolute immunity to macroeconomic fluctuations and market cyclicality. By analyzing the quarterly EPS dynamics, an investor sees a profit stream stripped of reporting time lags. This indicator measures the rate of change in net income, confirming the effectiveness of the current business strategy. The steady growth of the curve guarantees investment security, eliminating the risk of margin compression. This confirms the fundamental stability of the asset.

Competitors of Zymeworks Inc.

IBRX: Quarterly EPS earnings growth|IMCR - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Janux Pharma|Year-over-year net earnings per share growth for the last 12 months Arcus Corp (RCUS)|Year-over-year earnings per share growth for the last twelve months Tango Therapeutics (TNGX)|Year-over-year net earnings per share growth for the last 12 months iovance.com IOVA|Immatics - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Xencor Inc XNCR|CMPX - Year-over-year earnings per share growth for the last twelve months|REPL (Replimune Inc.) - Year-over-year earnings per share growth for the last 12 months|Lyell Immunopharma (LYEL) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months innate-pharma.com (IPHA)|Year-over-year net earnings per share growth for the last 12 months PYXS|CGEN - Net earnings per share growth for the trailing year|Year-over-year net earnings per share growth for the last 12 months IOBT (IO Biotech Corp)|Year-over-year earnings per share growth rate for the last twelve months STRO|Quarterly EPS earnings growth INKT (MiNK Therapeutics, Inc.)|Year-over-year earnings per one share growth for the last 12 months HOWL|Immix - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months alxoncology.com|Cue Biopharma (CUE) - Year-over-year earnings per share growth for the last twelve months|PDS Biotechnology Corporation - Year-over-year earnings per one share growth for the last 12 months|SONN (Sonnet BioTherapeutics Holdings, Inc.) - Quarterly EPS earnings growth|Quarterly EPS earnings growth MAIABiotech.com|Year-over-year earnings per share growth for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Year-over-year net earnings per share trend for the last twelve months|NextCure Corp - Year-over-year net earnings per share growth for the last 12 months|Leap Therapeutics Inc (LPTX) - Earnings per share growth in annualized terms for the last twelve months|INTS: Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share trend for the last twelve months SNSE|TOVX (Theriva Biologics) - Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Gritstone bio (GRTS)|Year-over-year earnings per share growth for the last twelve months Kineta Bio|Year-over-year net earnings per share growth for the last 12 months NexImmune Corporation (NEXI)|Quarterly EPS earnings growth TSBX|VCNX - Earnings per share growth in annualized terms for the last twelve months|Harpoon Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months